Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Cronos Group Inc (CRON) Price & Performance

BioNano Genomics IncTrade
Cronos Group IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Cronos Group Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Cronos Group Inc trades at $3.07 (market cap $1.14B). The key difference: Cronos Group Inc is far larger — about 83.5× BioNano Genomics Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOCRON
Market Cap
$13.66M$1.14B
Sector
HealthHealth
52-Week High
$4.92$3.27
52-Week Low
$1.06$2.30
Enterprise Value
$16.26M$341.13M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.

The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.

Cronos Group Inc

CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.

Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON